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ENHANCED RECOVERY AFTER SURGERY AND OPIOID-FREE 




The opioid epidemic is a public health crisis in the United States that impacts the 
lives of millions of people. There is a need for interventions aimed at minimizing 
opioid usage in clinical settings. The perioperative care period – consisting of the 
time before, during, and after surgery – is a time where interventions can be 
made in surgical and anesthesia practice to reduce the number of opioids used. 
Surgery and anesthesia are two areas where patients have traditionally been 
introduced to prescription opioids for the first time. Enhanced Recovery After 
Surgery pathways have been designed to integrate and improve surgical care for 
patients resulting in decreased length of stay in the hospital for surgical patients. 
Enhanced Recovery After Surgery pathways have also explored reducing opioid 
use during surgical care. Multimodal Analgesia and Opioid Free Anesthesia are 
two methods that have been researched and shown to be successful in limiting 
the perioperative use of opioids. Multimodal Analgesia and Opioid Free 
Anesthesia both reduce total perioperative opioid use and manage pain as 
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In the face of the opioid epidemic in the United States, the prescription and use 
of opioids for all causes faces intense scrutiny. Surgery and anesthesia are fields 
where opioids have long been a standard component of pain management 
protocols. The focus of this thesis is to analyze the impact of Enhanced Recovery 
After Surgery (ERAS) pathways and other perioperative techniques in reducing 
opioid use in surgical patients. In the following introduction, a brief summary of 
the opioid epidemic, and a history and background of ERAS pathways, with a 
focus on pain management protocols, will be presented. 
 
Opioid Use and Abuse: Implications for Surgery and Anesthesia 
The opioid epidemic is one of the greatest public health problems facing 
physicians in the U.S. It is associated with significant morbidity, mortality, and 
economic burden. For the first time in decades, there has been an increase in all-
cause morbidity and mortality in middle-aged white men and women. This 
increase has largely been attributed to drug abuse and overdose, which includes 
opioid abuse and its clinical complications (Case and Deaton 2015). 
Furthermore, recent data from the Centers for Disease Control and Prevention 
reports 218,000 people died of opioid-related overdoses between 1999 and 
2017. One study on the economic impact of the opioid abuse estimates that the 
societal cost of prescription opioid abuse is around $50 billion per year in the 
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U.S. (Oderda et al., 2015). Without changes in clinical practice and interventions 
to tackle opioid abuse, the problem will continue to worsen. One projection 
predicts that as many as 700,000 Americans could die of an opioid overdose in 
the next decade between 2016 and 2025 (Chen et al., 2019). While many of 
these projected overdose deaths will be attributed to illicit opioids, such as 
heroin, the contributing impact of prescription opioids to the opioid epidemic 
cannot be ignored.  
 
The opioid epidemic needs to be tackled from many different components of the 
healthcare system. Among the leading causes contributing to the opioid epidemic 
has been the opioid prescribing practices by physicians to treat both acute and 
chronic pain (Rosenblum et al., 2008). The increase in opioid prescriptions to 
manage pain was in part facilitated by an initiative during the 1990s to treat pain 
as the “fifth vital sign.”  In 2016, the American Medical Association voted to stop 
treating pain as a vital sign in favor of more responsible and evidence-based pain 
management practices (Scher et al., 2018). Pain management practice has now 
shifted to minimizing the use of opioids to treat pain.  
 
Surgery and anesthesia present opportunities for pain management interventions 
in a field of medicine where there has traditionally been a high usage of opioids 
to treat pain. Surgical events and anesthesia are often the “gateway” for patients 
taking opioids for the first time (Waljee et al., 2017).  Studies across several 
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surgical fields have suggested that opioids prescribed during and after surgery 
are associated with long term opioid usage with the potential for opioid misuse 
and overdose (Hah et al., 2017). One study on a variety of patients undergoing 
both minor and major surgeries showed that about 6% of opioid-naïve patients – 
who have never used opioids – developed a long-term opioid-dependence after 
they underwent surgery (Brummett et al., 2017). The dosage of opioids 
administered preoperatively is also a risk factor to further opioid-dependence 
postoperatively. A study on opioid use in knee arthroplasty demonstrated that 
higher preoperative morphine doses were associated with increased risk of 
developing postoperative opioid-dependence (Goesling et al., 2016).  
 
The literature suggests that interventions to minimize opioids must be considered 
during preoperative, intraoperative, and postoperative periods. As surgery and 
anesthesia have become implicated as contributors to the opioid problem, 
changes in clinical practices are necessary to reduce opioid usage. There is 
much interest in eliminating or reducing opioids as part of anesthesia pathways 
(Egan 2019).  The proposed hypothesis of the research is that the reduction of 
opioid usage during surgery will reduce the number of surgical patients being 
introduced to opioids. As a result of reduction in exposure to opioids, fewer 
patients will develop a future opioid dependence. While it might not be feasible to 
eliminate opioids entirely from surgical pain management protocols, a reduction 
in opioid use could certainly have a large impact on reducing opioid dependence 
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following surgeries. The rest of this thesis will explore the field of ERAS and 
perioperative pain management protocols, such as multimodal analgesia and 
opioid-free anesthesia. 
 
Background on ERAS 
Perioperative care consists of the entire time a patient is being cared for by the 
surgical team from admission to discharge. ERAS pathways – which has evolved 
from “Fast Track Surgery” or “Rapid Recovery” – were pioneered in Europe in the 
late 1990s as multimodal evidence-based approach to caring for colorectal 
surgical patients in the perioperative period. Prior to ERAS, there was no 
consensus or standardization of perioperative care. Perioperative care was 
managed on a case-by-case basis without a defined protocol. ERAS pathways 
aimed to remove the “guesswork” from perioperative care and replace it with 
evidence-based interventions that would help patients recover faster from 
surgery. The aims of ERAS were three-fold: 1. decrease length of stay (LOS) of 
patients in the hospital, 2. decrease surgical complications, and 3. increase 
patient satisfaction (Tanious, Ljungqvist, and Urman 2017). 
 
Early ERAS interventions were successful in achieving the goals of decreasing 
LOS and decreasing surgical complications. One of the first published ERAS 
studies was able to decrease the LOS of open sigmoidectomy patients from 5-10 
days to 2 days (Kehlet and Mogensen 1999). The success of ERAS pathways in 
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reducing LOS for colorectal surgery has been replicated many times at different 
institutions. A meta-analysis of randomized control trials (RCTs) that compared 
colorectal surgery ERAS pathways to previous hospital protocols demonstrated a 
reduction in LOS by 2 days and a decrease in complication rates by 50% 
(Varadhan et al., 2010). Importantly, there has not been an increase in 
readmission rates for patients in ERAS pathways (Greco et al., 2014). This 
suggests that ERAS pathways are not just discharging patients before they are 
ready, but rather that the patients are recovering faster. Following success in 
colorectal surgery, ERAS pathways have been adopted by other surgical fields. 
Decreased LOS following ERAS implementation has been reported in 
gynecological surgery, spinal surgery, and orthopedic surgery (Modesitt et al., 
2016; Greco et al., 2014; Deng et al., 2018). Some studies have also reported 
that ERAS programs have helped decrease total hospital costs, which likely are 
attributed to the decreased LOS and reduced complications (Jung et al., 2018).  
 
The success of ERAS in maintaining patient satisfaction is more difficult to 
define; however, there are no indications that ERAS has had any negative impact 
on the patient experience. A review of orthopedic surgery ERAS pathways 
concluded that there was a high patient satisfaction due to the patients’ ability to 
return home and return to normalcy faster (Jones et al., 2014). Similar findings of 
improved or high patient satisfaction have been reported in colorectal surgery, 
gynecological surgery, spinal surgery, and other orthopedic surgery ERAS 
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programs (Debono et al., 2019; Partoune et al., 2017; Philp et al., 2015; Specht 
et al., 2018). Patient satisfaction can be a difficult outcome to evaluate, however 
studies and data collection on patient satisfaction are currently being conducted.  
Nevertheless, it is encouraging that patients are receptive to the ERAS pathways 
and do not feel as if they are being discharged too quickly after surgery.    
 
To date, much of the research on ERAS pathways has been conducted in 
Europe. In the U.S., it has taken some time to implement ERAS into surgical 
protocols in hospitals beyond academic institutions. One reason that hospitals 
have not widely adopted ERAS is that the protocols require a large investment of 
resources due to the multidisciplinary nature that requires integration throughout 
the hospital. A systemic review of ERAS protocols identified resistance by 
physicians and lack of resources as main barriers to implementation. Rural 
hospitals face challenges in dealing with complex patients because they may 
require more specialized care than the hospital can provide (Stone et al., 2018).  
 
A Description of ERAS Protocols 
ERAS pathways are a multidisciplinary effort consisting of a series of evidence-
based practices, such as multimodal pain control, that when combined help 
patients recover faster from surgery. The ERAS team consists of surgeons, 
anesthesiologists, nurses, administrators, care coordinators, physical therapists, 
and other staff specialized for carrying out the specific protocols (Ljungqvist, 
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Young-Fadok, and Demartines 2017). Figure 1 describes the general roles of 
different care providers in an ERAS protocol. Generally, the physicians are the 
leaders of the ERAS team. Each member of the ERAS team is important as they 
carry out specific roles that are important to the ERAS protocols. Good 
communication and integration between the various providers are necessary for 
a successful ERAS protocol. Compliance to all elements of the ERAS protocol 
has been cited in the literature as an important contributor to successful ERAS 
programs and a common barrier in failed ERAS programs (Pedziwiatr et al., 
2015). 
 
The philosophy behind ERAS pathways is that limiting physiologic stress on 
patients will allow the patient to recover faster. As explained in the previous 
section, the ERAS pathways have been very successful in reducing LOS and 
decreasing surgical complications. Generally, ERAS protocols focus on five 
periods for interventions: 1. preadmission, 2. preoperative, 3. intraoperative, 4. 
postoperative, and 5. postdischarge (Figure 2). Some institutions have 
developed a designated service called the Perioperative Surgical Home (PSH) to 
help ensure adherence and continuity of care as patients are in the various 
stages of their surgical care. The idea of the PSH is to have a team-based 
approach aimed at coordinating care between various providers in order to 
effectively care for the surgical patient. Two separate studies on the 
implementation of PSH – one at a Veterans Affairs Hospital and the other at 
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Vanderbilt University – each demonstrated a high adherence of about 80% or 
more to all ERAS pathway components (Alvis et al., 2017; McEvoy et al., 2016). 
As noted previously, compliance is a barrier to successful implementation of 
ERAS program, and PSH has been shown as a successful solution to increasing 
ERAS compliance. However, one problem with the PSH is that it can be quite 
expensive to implement a designated service specifically for ERAS. As 
previously described, many hospitals lack the resources and specialized 
personnel to be able to implement all elements of an ERAS program. Thus, 
implementation of PSH may not be feasible in some hospitals due to limitations 
on resources and personnel. Nevertheless, the PSH model works very well in 
clinical practice with an ERAS program and should be considered when 





Figure 1. The Role of Providers in an ERAS Protocol. Taken from (Tanious, 











The ERAS Society – an academic organization dedicated to ERAS 
implementation and innovation – has published guidelines for various surgical 
specialties. ERAS guidelines have been published for colorectal, gynecological, 
thoracic, and cardiac surgery to just name a few (Ljungqvist, Scott, and Fearon 
2017). For simplification, the following description of ERAS protocols will focus 
on colorectal surgery. Colorectal surgery was the field in which ERAS protocols 
were first developed and has served as the basis for adaptation of ERAS to other 
surgical fields. As described previously, the interventions are aimed at minimizing 
stress to the patient to promote a rapid recovery and to limit complications. Table 
1 lists some of the evidence-based guidelines put together by the ERAS Society 
for colorectal surgery. ERAS interventions can generally fall into three categories: 
pain control, maintenance of fluid balance, and prevention of complications 
(Gustafsson et al., 2019; Carmichael et al., 2017). The clinical and physiological 
basis for each of these guidelines is beyond the scope of this thesis. The focus of 
the remainder of this introduction will be on opioid sparing pain management 








Table 1 (continued). 
 




Multimodal Analgesia (MMA)  
A balanced general anesthesia protocol requires three elements: antinociception, 
unconsciousness, and immobility. First, antinociceptive agents inhibit the 
propagation of harmful stimuli (i.e. surgical incision) through the sensory nervous 
system. Second, hypnotic agents are usually inhaled to produce the state of 
unconsciousness in the patient. Third, muscle relaxants contribute to keeping the 
patient immobile for the duration of the surgery. Table 2 summarizes the drugs 
used to achieve each step of general anesthesia. Some drugs achieve more than 
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one effect on the patient. For example, ketamine is used primarily as an 
antinociceptive agent, but also contributes to maintaining the state of 
unconsciousness. When all the drugs are combined as part of a balanced 
general anesthesia protocol, this decreases the dosages of each individual drug 
required to maintain the anesthetic state in the patient (Brown, Pavone, and 
Naranjo 2018). 
 
Historically, opioids have been relied on as the primary antinociceptive agent 
used in general anesthesia protocols. As discussed in prior sections, this use of 
opioids in general anesthesia has likely contributed to the state of the current 
opioid epidemic. Antinociceptive agents are the target of multimodal anesthesia 
(intraoperative) and multimodal analgesia (preoperative or postoperative) 
protocols. Multimodal anesthesia has emerged as a way to limit the doses of 
opioids prescribed in the perioperative period. The concept of multimodal 
anesthesia is based on using a variety of antinociceptive agents to decrease 
dosages and harmful effects of each individual antinociceptive agent. Some 
antinociceptive agents used as part of multimodal analgesia are opioids, non-
steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, ketorolac), 
acetaminophen, gabapentinoids (pregabalin, gabapentin), N-methyl-D-aspartate 
(NMDA) agonists (ketamine, magnesium), alpha 2 agonists (clonidine, 
dexmedetomidine), local anesthetics (nerve blocks, bupivacaine), lidocaine, 
corticosteroids (dexamethasone) and a few others (Table 3). While there are 
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variations in different multimodal analgesia protocols, all multimodal analgesia 
protocols use some combination of the drugs mentioned above (Wick, Grant, and 
Wu 2017; Nimmo, Foo, and Paterson 2017). 
 
Opioid Free Anesthesia (OFA)  
OFA is a new technique that is being used with the same goal of minimizing 
opioid use in general anesthesia protocols. OFA eliminates opioids entirely from 
the perioperative pain management of the patient.  
 
 
Table 2. Components of Balanced General Anesthesia.* Column I display the 
achieved effect; Column II displays the primary effect of the drug; Column III 
shows secondary effects of the drug. 
 
 




Table 3. Common Drugs used to achieve Multimodal Analgesia*.  
 
 





The primary aim of this thesis is to analyze the effectiveness of specific ERAS 
interventions in minimizing the perioperative use of opioids. Opioid-reducing 
interventions, specifically opioid-sparing MMA and opioid-free anesthesia (OFA) 
will be evaluated. Studies will be evaluated on the following: 
1. Ability to reduce opioid use in the perioperative period 





MMA Studies to Minimize Opioid Use 
In the literature, MMA studies have been mostly successful at reducing opioid 
use in the perioperative period. MMA interventions have been made in the 
preoperative, intraoperative, postoperative, and throughout the entire 
perioperative period. MMA is a common component of ERAS programs and 
studies have investigated MMA both in the context ERAS programs and on its 
own. MMA protocols have been used to manage pain for a variety of different 
surgery fields with varying levels of success.  
 
A large retrospective study of 569 cesarean section patients investigated the 
effect of altering an MMA protocol with the primary aim of reducing opioid use 
during the entire hospital stay while still maintaining pain relief (Smith et al., 
2019). Prior to intervention, the standard for postoperative pain relief was a 
scheduled dose of combination opioids with acetaminophen (oxycodone) along 
with intravenous and oral NSAIDs (ketorolac and ibuprofen. Researchers altered 
the MMA protocol by eliminating combination opioids from the order set and 
replaced by NSAIDs and acetaminophen. Opioids were still available to patients 
to manage pain, but only at a patient’s request. In addition to altering the MMA 
protocol, the researchers focused interventions to reduce discharge opioid 
prescriptions for patients and to improve patient education on safe opioid use. 
Table 4 compares the difference in pain medications that were used 
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preintervention and postintervention. In the postintervention group, there was a 
significantly higher use of acetaminophen (2,340 mg to 1,391 mg) and a 
significantly lower total opioid use over the entire hospital stay (30 MME to 120 
MME), measured in morphine milligram equivalents (MME). The total opioid 
reduction was 75% from preintervention to postintervention. There was also an 
increase from 6% to 19% of patients who used no opioids during the hospital 
stay. Additionally, there was no change in overall pain scores between the 
groups. The study concluded that their MMA protocol was able to minimize 
opioids without sacrificing the quality of pain management. 
 
Table 4. Drugs Administered Pre- and Post-MMA Protocol for Cesarean 




* Taken from (Smith et al., 2019) 
 
 
In laparoscopic Roux-en-Y gastric bypass patients, a retrospective study of 885 
patients compared opioid usage before and after implementation of a 
preoperative and postoperative MMA protocol (Horsley et al., 2019). This study 
operated in the context of an ERAS pathway. Prior to the MMA protocol opioids 
were the foundation of pain management. Postoperatively, patients were allowed 
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self-administered morphine and then were transitioned to an oral opioid 
(oxycodone). The MMA protocol introduced celecoxib (NSAID) and 
acetaminophen as the primary pain medications to be given both preoperatively 
and postoperatively. In the immediate postoperative period, patients could self-
administer morphine for lingering pain. Oral opioids were allowed postoperatively 
for any remaining pain, but only at the patient’s request. The results showed a 
statistically significant decrease in total opioid use, significant decrease in 
maximum pain scores, and no change in mean pain score from before to after 
implementation of MMA (Table 5). However, there was a slight increase in the 
likelihood of unspecified minor complications and pulmonary complications with 
the MMA protocol. There was no significant difference in major complications and 
bleeding complications between the two groups.  
 
Table 5. Total Opioids Administered and Pain Scores for Gastric Bypass.* 
 
 




A prospective cohort study on Head and Neck surgery patients instituted an 
MMA protocol that had the primary aim of measuring inpatient postoperative 
opioid use (Du et al., 2019). The MMA protocol consisted of intravenous 
acetaminophen and ketorolac (NSAID) given for mild pain every 4-6 hours 
postoperatively for the first 48 hours. Additionally, patients were given pregabalin 
preoperatively for major surgeries. Postoperatively, patients were allowed self-
administered intravenous opioids as needed without restrictions for 24-48 hours 
and then could request oral opioids as needed for lingering pain. A matched 
cohort of 220 patients were compared before and after the implementation of the 
MMA protocol. The results of the study showed mixed success in the ability of 
the MMA protocol to reduce total opioid use. The MMA protocol was able to 
produce significant one-third reduction in the mean opioid use within the first 24 
hours after surgery. However, there was no significant difference in mean total 
opioid use when averaged over the entire hospital stay. This deficit in maintaining 
the decrease in total opioid use was attributed to the design of the MMA protocol. 
Researchers reasoned that the ketorolac should have been included in the 
protocol for longer than 48 hours. Baseline opioid use and chronic pain in one-
third of patients were other potential reasons the researchers listed as why total 
opioid use over the entire hospital stay did not decrease. Regarding pain 
management, there was no significant difference in pain scores reported 
between the pre-protocol and post-protocol groups at 24 hours after surgery or at 
discharge. Furthermore, there were no significant differences in LOS or rates of 
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complications (i.e. bleeding) between the groups. The study concluded that MMA 
protocols have potential to safely reduce total opioid use in head and neck 
surgery patients, but there still needs to be more research into the design of 
MMA protocols.  
 
A large prospective study of 607 gynecological oncology surgery patients 
investigated the outcomes of an ERAS program that included an unspecified 
opioid-sparing MMA protocol intraoperatively and postoperatively (Meyer et al., 
2018). In addition to MMA, the ERAS program included common ERAS 
components such as nutritional counseling, maintaining fluid balance, early 
feeding, and a several other perioperative interventions. The study reported 
75.2% of patients were compliant to at least 70% of the ERAS protocol elements.  
The ERAS program patients showed in a statistically significant 39% reduction in 
intraoperative opioid use as well as a significant reduction in postoperative opioid 
use at days 0, 1, 2, and 3 compared to pre-ERAS patients (Figure 3). 
Furthermore, in the pre-ERAS group 0% patients reported opioid-free on days 1 
to 3 postoperatively, while in the post-ERAS group 16% of patients reported 
opioid-free on days 1 to 3 postoperative. There was no difference in overall pain 
scores between the pre-ERAS and post-ERAS groups. Other results from the 
post-ERAS group included a decrease in median LOS and a decrease in 
intraoperative complications. There was no difference in rates of surgical 
complications, reoperation, readmission, or 30-day mortality between the groups. 
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This ERAS program for gynecological oncology was able to successfully reduce 
perioperative total opioid use, while continuing to be successful in achieving 
other ERAS goals such as decreasing LOS and reducing surgical complications. 
 
 
Figure 3. Postoperative Opioid Use Pre-ERAS and Post-ERAS for 
Gynecological Oncology Patients. Taken from (Meyer et al., 2018). 
 
 
Barker et al. did a retrospective chart review of 560 patients undergoing 
outpatient breast surgery to see the effect of applying MMA to reduce opioid use 
for an outpatient surgery (Barker et al., 2018). The patients were divided into 4 
separate groups. Group 1 received no preoperative analgesia; Group 2 received 
IV acetaminophen; Group 3 received preoperative oral gabapentin and 
acetaminophen; and Group 4 received preoperative oral gabapentin, 
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acetaminophen, and celecoxib (NSAID). Figure 4 shows that groups 3 and 4 
each had a significant reduction in post anesthesia care unit opioid use and a 
reduction in LOS for the patients. Although, the reduction in LOS was not 
statistically significant. Additionally, groups 3 and 4 also had a significant 
reduction in initial postoperative pain scores and maximum pain scores. These 
results suggest that preoperative administration of non-opioid pain medications 
can be effective as part of an MMA to decrease postoperative opioid use and to 
improve pain management overall in outpatient breast surgery.  
 
 
Figure 4. Post Anesthesia Care Unit Opioid Use and LOS for Breast Surgery 
Patients. Group 1 (green), Group 2 (blue), Group 3 (red), and Group 4 (purple). 





Another retrospective review of patients undergoing breast surgery implemented 
an MMA protocol as part of an ERAS program (Chiu et al., 2018). The MMA 
protocol consisted of interventions at the preoperative, intraoperative, and 
postoperative periods. Preoperatively, patients received oral acetaminophen, oral 
gabapentin. Intraoperatively, patients received regional anesthesia (nerve blocks) 
in addition to an anesthetic protocol that minimized opioids as much as possible. 
Postoperatively, patients were given ibuprofen for mild pain, oral combination 
opioids with acetaminophen (oxycodone) for moderate pain, and intravenous 
opioids for severe pain. The overall compliance to components of the MMA 
protocol were greatly improved as part of the ERAS program. MMA elements 
such as preoperative acetaminophen improved from 17% pre-ERAS to 89% 
post-ERAS. Similar improvements to compliance were also found for use of 
preoperative gabapentin and use of intraoperative regional anesthesia. The 
ERAS group showed a significant reduction in total opioid use, intraoperative 
opioid use, PACU opioid use, and hospital floor opioid use (Table 6). The 
maximal pain scores were also significantly lower in the ERAS group. 
Additionally, there was a decreased incidence of postoperative nausea and 
vomiting in the ERAS group. Overall, researchers concluded that this ERAS 
program with breast surgery patients was able to successfully implement MMA 





Table 6. Opioid Use Pre-ERAS and Post-ERAS for Breast Surgery. * 
 
* Taken from (Chiu et al., 2018). 
 
 
A retrospective study of 24 outpatient oral surgery patients tracked the amount of 
opioid prescriptions that were filled by patients after discharge (Magraw et al., 
2018). The goal of the study was to evaluate the efficacy of a perioperative MMA 
protocol in reducing opioid use after patients went home from the hospital. The 
MMA protocol for oral surgery consisted of intraoperative pain management with 
local anesthesia and intravenous ketorolac (NSAID) and postoperative pain 
management with ibuprofen (NSAID) and a prescription combination opioid with 
acetaminophen. The researchers tracked how many patients filled their opioid 
prescriptions. The results displayed that 10 of 24 patients filled no opioid 
 
27 
prescription and 8 of 24 filled only 1 opioid prescription after implementation of 
the MMA protocol. While this study contained a small sample size, it 
demonstrated the potential for MMA protocols in decreasing opioid use for 
patients after they are discharged from the hospital.   
 
While many of the studies on MMA have been successful in reducing 
perioperative opioid use, not all studies have been successful. One randomized 
controlled trial had the primary aim of reducing total opioid use in cesarean 
section patients (Hadley et al., 2019). The intervention being analyzed in this 
study was an MMA protocol focused on the preoperative and intraoperative 
periods consisting of administration of intravenous acetaminophen, 
subcutaneous bupivacaine (nerve block), and intramuscular ketorolac (NSAID). 
120 patients were randomized to control and intervention groups. Both groups 
were given the same intraoperative and postoperative pain management plans. 
The postoperative pain medications given were oral ibuprofen and oral 
combination hydrocodone with acetaminophen. The results showed no difference 
in postoperative opioid use when comparing the control and intervention groups. 
There was no difference in opioid use between the groups in the first 48 hours 
after surgery. Additionally, researchers tracked the time when patients took their 
first opioid and there was no difference between the groups. One potential 
reason that researchers gave for the lack of success of the study was the over-
prescription of postoperative opioids in both groups. On postoperative day 7, 
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patients in the control and intervention groups had an average of 18 and 19 
opioid tablets leftover, respectively.  
 
OFA Studies to Minimize Opioids 
A lot of the studies on OFA have been based on case reports that were 
specifically tailored for patients. One report of a 35-year-old female with cerebral 
palsy patient requested an OFA protocol because of previous adverse side 
effects to opioids (Chin and Lewis 2019). The patient was undergoing a spinal 
fusion for correction of scoliosis. Preoperatively, erector spinae plane nerve 
blocks for local anesthesia were performed. Intraoperatively, dexamethasone, 
dexmedetomidine, and ketamine were administered to prolong the nerve block 
effects. Postoperatively, ketorolac and acetaminophen were given to the patient 
as needed for pain. The patient reported satisfactory pain control with a resting 
pain score of 0/10. The case showed how local anesthesia has the potential to 
perform satisfactory pain relief during surgery without the need for opioids.  
 
Another case of a 40-year-old morbidly obese female designed an OFA protocol 
for bariatric surgery in order to prevent potential postoperative respiratory 
complications as a side-effect of opioids (Aronsohn et al., 2019). Intraoperatively, 
antinociceptive agents used as part of the protocol consisted of ketamine along 
with dexamethasone and acetaminophen. Postoperatively, the patient was given 
ketorolac for pain. The patient came out of the surgery successfully without any 
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complications. The case identified ketamine as a key agent to OFA protocols due 
to its ability to produce similar analgesia as opioids, while avoiding some opioid 
side effects such as respiratory complications and postoperative nausea.  
 
A third case report of an OFA protocol was designed for a tricuspid valve 
replacement was designed for a 30-year-old male with a history of opioid 
addiction (Cardinale and Gilly 2018). Preoperatively, the patient received 
ketamine, IV acetaminophen, and dexamethasone. Intraoperatively, the patient 
continued to receive ketamine as well as dexmedetomidine and lidocaine. 
Postoperatively, the patient received a combination of non-opioid analgesics 
including acetaminophen, aspirin, celecoxib, and pregabalin. The patient 
reported a 6/10 pain at rest at postoperative day 1 and he required minimal pain 
medication by postoperative day 3. At follow-up visits, the patient’s toxicology 
reports remained negative for opioids. This case showed how OFA can present 
quality alternative for patients who do not want to take opioids due to a history of 
opioid abuse.  
 
The case reports mentioned show that in clinical practice it is possible to 
eliminate opioids entirely from the anesthesia protocol. Case reports lack the 
power to make definitive statements about the efficacy of OFA for a general 
patient population. Only a few large-scale studies have analyzed the impact of 
OFA reduction on total opioid use. One observational study implemented an 
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ERAS protocol with OFA for breast surgery lumpectomy patients with the goal of 
eliminating prescription opioids at discharge (Rojas et al., 2018). The study 
compared opioid use between an intervention group using OFA as part of an 
ERAS pathway to a control group using OCA that was previous standard at the 
hospital. The OFA intervention worked throughout the entire perioperative period. 
Preoperatively, patients were given acetaminophen and gabapentin; 
intraoperatively, patients were given ketorolac (NSAID); and postoperatively, 
patients were given ibuprofen (NSAID) for pain as needed. The study was able to 
successfully eliminate postoperative opioid use entirely from the OFA group and 
maintained high compliance to the elements of the OFA protocol (Table 7). 
There were no differences in pain scores between the intervention and control 
groups throughout the study. Additionally, there were no major complications 




Table 7. Perioperative Medications Given to Lumpectomy Patients. * 
* Taken from (Rojas et al., 2018) 
 
 
A historical prospective study evaluated the effect of a colorectal ERAS program 
in reducing the opioid prescribing practices of physicians (Brandal et al., 2017). 
The ERAS program used both OFA and MMA elements. Patients were allowed 
postoperative intravenous opioids only if other pain medications did not alleviate 
pain. Patients were compared before and after ERAS implementation. The study 
demonstrated that even though there was an increase in physicians using OFA 
and MMA methods in the perioperative period, physicians still prescribed opioids 
at a high level postoperatively. The incidence of opioid prescription at discharge 
was 85% before ERAS and 78% after ERAS, but this decrease was not 
statistically significant. Researchers found that as many as 70% of patients who 
were prescribed opioids at discharge had low pain scores that did not require 
opioids to manage. This study showed that interventions to standardize physician 
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prescribing practices of discharge opioids need to be considered as part of ERAS 
programs. 
 
A retrospective study in lumbar spine surgery patients compared a matched 
cohort of 36 patients who were divided equally into ERAS programs with either 
OCA or OFA (Soffin et al., 2019). Patients in the OCA and OFA groups both 
received the same intraoperative anesthesia drugs except the OCA group added 
an opioid for pain. In addition, both groups received the same preoperative and 
postoperative MMA drugs that used opioids only for severe pain scores. The 
results showed a significant decrease in the total perioperative opioid 
consumption and PACU opioid consumption for the OFA patients compared to 
the OCA patients (Figure 6). Also, there was not a significant difference in pain 
scores between the groups. The compliance to the ERAS protocols was 91.4% 
for the study. This study showed that ERAS programs that use both OFA and 





Figure 5. Total Opioid Consumption and PACU Opioid Consumption in 





The studies analyzed in this paper have demonstrated that both MMA and OFA 
can be successful in reducing the number of opioids used in the perioperative 
period for both inpatient and outpatient surgical patients. Additionally, the 
reduction in opioid usage has not come with a tradeoff in the quality of pain 
management as patients have continued to report similar pain scores before and 
after implementation of MMA or OFA protocols.  
 
MMA has had more extensive research done on its efficacy in reducing opioid 
use both independently and as part of an ERAS protocol. Therefore, due to the 
success of MMA protocols, the ERAS Society has included MMA as part of their 
recommendations for an ERAS program. As the mentioned studies have shown, 
there are different ways to the implement an MMA protocol depending on the 
surgery, requirements of the patients (Beverly et al., 2017) and to add to that 
hospital culture and pre-existing policies can also influence protocol 
development.  By managing pain via local and systemic analgesic pathways, 
prescribers are able to lower the dose of each type of pain medication while still 
providing successful pain relief. One of the effective MMA elements was a simple 
change to remove opioids from the standard protocol in postoperative pain care. 
Smith et al. and Horsley et al. both made this change to make opioids optional for 
patients and it successfully reduced total opioid use in both studies. Another 
factor that warrants attention is the post discharge opioid prescribing practices of 
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physicians. Hadley et al. and Brandal et al. both found that too many patients 
were being prescribed post discharge opioids when patients did not have pain 
that required them. Leftover opioid prescriptions can be a risk for future opioid 
abuse. Standardization of post discharge opioid prescribing practices should be 
worked into MMA protocols to prevent patients from receiving excess opioids.  
 
OFA has been less extensively researched, but the ability to reduce opioids 
almost entirely from the perioperative period is promising for patients who cannot 
or do not want to take opioids. Additionally, OFA avoids potential adverse side-
effects associated with opioid use. For example, in patients with prior long-term 
opioid use or abuse, there have been reports of patients becoming desensitized 
to the opioids, which prevents the opioids from producing an analgesic effect on 
these patients (Lavand'homme and Steyaert 2017). The exacerbation of pain due 
to developing tolerance to opioids is called opioid-induced hyperalgesia. Other 
adverse opioid side effects can also be limited such as postoperative nausea, 
constipation, and respiratory depression (Benyamin et al., 2008). When 
considered as part of an ERAS pathway, OFA could be a way to help patients 
recover faster by preventing some of the complications caused by opioid therapy. 
Currently, OFA presents an alternative for pain management in the anesthesia 
protocol for patients who may have a contraindication to using opioids or have 
suffered from opioid abuse in the past. More research needs to be done to 
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identify the elements of OFA that are effective and to make sure that OFA is 
adaptable to a larger population of patients.  
 
In the studies analyzed in this paper, MMA and OFA protocols have both been 
largely found to be safe for patients. However, this does not mean that MMA and 
OFA do not present risks to patients. One risk for patients is the undertreat of 
surgical pain. The MMA and OFA studies above demonstrated no differences in 
pain scores when compared to previous pain management protocols. Another 
risk is bleeding complications from increased use of NSAIDs in MMA and OFA 
protocols. NSAIDs are associated with an increased risk of gastrointestinal 
bleeding and ulcers. These risks of undertreating pain and bleeding were not 
endorsed by any of the studies presented in this paper. Nevertheless, 
researchers should be conscientious in tracking these risks in all studies 




A main challenge to successful implementation of ERAS protocols is adherence 
to the guidelines. Not all studies elaborate on their compliance rates in the 
publications. Compliance could be a significant confounder in the ability of an 
ERAS program to be successful. As explained previously, ERAS is 
multidisciplinary and multimodal. Good communication and support from 
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hospitals is necessary for a successful outcome of the ERAS program. 
Additionally, some of the studies analyzed above were not part of an ERAS 
protocol at all. An ERAS program can help integrate the entire perioperative care 
of a patient and impact the success of MMA and OFA in reducing total opioid 
use.  
 
2. Cohort Size 
Another limitation in the OFA studies is the cohort size. There have not been 
many large-scale studies investigating the efficacy OFA. Studies such as Soffin 
et al. focused on a retrospective analysis of a small group of patients. There is a 
need for prospective studies and RCTs to compare the outcomes between OFA 
and OCA.  
 
3. Long-term outcomes 
The MMA and OFA studies analyzed in this study have been largely successful 
in reducing perioperative total opioid use. The limitation of these studies is that 
they have only followed patients in the perioperative hospital period. The main 
goal of MMA and OFA is to prevent chronic opioid use and misuse for patients in 
the future. There is a need for more prospective long-term studies that analyze 
the impact that these perioperative pain management methods may have on the 
patient experience long-term. Some potential long-term outcomes to look at 
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Beloeil et al. is conducting an RCT of patients undergoing cardiac surgery with 
OFA. Patients were randomized to an OCA or an OFA protocol. The study will 
address the limitations in previous OFA studies by being a prospective RCT 
study and including a larger cohort of 400 patients. This study will be focusing on 
immediate postoperative opioid-related adverse events, such as respiratory 
issues (Beloeil et al., 2018). More studies should aim to follow patients over a 
long-term period to track the ability of MMA and OFA to prevent future opioid 
abuse. 
 
Some researchers have proposed that ERAS protocols need to take a more 
personalized approach on a patient-by-patient basis. MMA and OFA could be 
areas for personalized treatment of patients in the perioperative period 
depending on patient preferences and patient’s past medical history. A 
personalized approach to follow-up care could be applied for opioid use to 
monitor how much opioids patients are using once they are discharged from the 
hospital. MMA and OFA can reduce opioid use in the hospital environment, but 
these protocols need to be reinforced with strict opioid prescribing practices by 
physicians. The study by Brandel et al. showed that although OFA methods were 
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implemented, the effects on reducing opioids were minimized by physicians 
prescribing opioids indiscriminately in the postoperative period. There are efforts 
being made now to reduce and regulate opioid prescribing practices. 
Nevertheless, a CDC report states that opioid prescribing was three times as 
high in 2015 as in 1999 (Guy et al., 2017). MMA and OFA are only one tool to 






The current opioid epidemic in the U.S. necessitates interventions that will 
minimize or eliminate opioid use altogether in clinical practice. MMA and OFA as 
part of an ERAS program have been shown to be successful surgical 
interventions that reduce opioid use in a field of medicine where opioids have 
previously been used indiscriminately. Not only do MMA and OFA reduce opioid 
use, but they are as effective if not more so than previous opioid containing 
protocols. MMA should be used widely as part of surgical protocols. OFA may 
not always be required, but it is a viable alternative to OCA in cases where 
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